Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02018419
Other study ID # ITL-014-TACT-MBC
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date March 2014
Est. completion date March 2014

Study information

Verified date April 2015
Source Immunovative Therapies, Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I/II study is designed to compare different treatment schedules of a personalized anti-cancer vaccine protocol which combines the cryoablation of a selected metastatic lesion with intra-tumor immunotherapy. The cryoablation causes the tumor to release tumor-specific antigens into the surrounding environment. The injection of bioengineered allogeneic immune cells, AlloStim(TM), into the lesion is designed to modulate the immune response and educate the immune system to kill other tumor cells.


Description:

The study will assess three different dosing schedules. A standard 3 plus 3 study design will be used. The starting dose for each dosing schedule will be escalated in subsequent groups of patients. The study will evaluate safety of increased frequency of AlloStim (TM) dosing and anti-tumor effect of the new proposed dose and frequency schedule.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Women w/ histologically/cytologically confirmed breast carcinoma

2. Documented progressive metastatic disease not amenable to curative surgery/radiotherapy

3. Age =18 and =70 years

4. Prior treatments that included capecitabine and both an anthracycline and a taxane drug and resistant to taxane therapy

1. ER+ patients: minimum cumulative dose of anthracycline (= 180 mg/m² of doxorubicin or = 300 mg/m² of epirubicin) or resistance to anthracycline, capecitabine and anti-hormonal therapy

2. Resistance is defined as tumor progression while receiving treatment or progression within 4 months of the last dose in the metastatic setting, or recurrence within 12 months in the neoadjuvant/adjuvant setting

5. Post-menopausal ER+ and/or PR+ must have received at least 2 lines of prior anti-estrogen therapy, which includes an aromatase inhibitor

6. Her2+ patients: at least 1 Her2+ targeted regimen containing trastuzumab alone or with pertuzumab/lapatinib. Trastuzumab/pertuzumab must have been discontinued at least 4 weeks before treatment

7. Prior radiation therapy completed >4 weeks before treatment

8. Measurable disease according to revised RECIST v.1.1 guidelines with at least 1 lesion deemed to be safely accessible for serial biopsy

9. ECOG <2

10. Adequate hematological function

1. Absolute granulocyte count = 1,500/mm3

2. Platelet count = 100,000/mm3

3. PT/INR = 1.5

4. INR correctable to = 1.5 or a PT/PTT correctable to normal limits. Patients receiving anti-coagulation treatment with agent such as warfarin/heparin may participate. For patients on warfarin, INR should be monitored weekly prior to any intervention to assure INR is stable. Heparin/warfarin must be withheld before biopsy

5. Hemoglobin = 9 g/dL (may be corrected by transfusion)

11. Adequate organ function

1. Creatinine = 1.5 mg/dL

2. Total bilirubin = 1.5 times ULN

3. Alkaline phosphatase=2.5 times ULN (=5 times normal if liver involvement)

4. Aspartate aminotransferase (AST/SGOT) = 5.0 times ULN

5. Alanine aminotransferase (ALT/SGPT) = 5.0 times ULN

12. EKG without clinically relevant abnormalities

13. Pre-menopausal with child bearing potential subjects must use adequate contraception

14. Informed consent in the native language of the subject

Exclusion Criteria:

1. Peritoneal carcinomatosis

2. Moderate-large ascites accumulation requiring/likely to require paracentesis

3. Clinical/radiological evidence of brain metastasis/leptomeningeal involvement

4. Pulmonary lymphangitis/symptomatic pleural effusion (grade = 2) that results in pulmonary dysfunction requiring active treatment

5. History of 2nd primary malignancy, except: bilateral breast carcinoma, in situ carcinoma of the cervix, adequately treated non-melanomatous carcinoma of the skin, and other malignancy treated at least 5 years with no evidence of recurrence

6. >3 prior chemotherapy regimens for metastatic disease

7. History of severe hypersensitivity to monoclonal antibody drugs/any contraindication to study drugs

8. Pregnant or breast feeding

9. Any serious, concurrent uncontrolled medical disorder

10. Prior hepatectomy, liver chemoembolization, liver cryoablation/ radiofrequency ablated

11. Symptomatic pulmonary disease

12. Bevacizumab (Avastin®) within 3 weeks of accrual

13. Prior allogeneic bone marrow/stem cell or solid organ transplant

14. Chronic use (> 2 weeks) of greater than physiologic doses of corticosteroid agent (dose equivalent to > 10 mg/day of prednisone) within 30 days of the first day of study treatment. Topical and inhaled corticosteroids are permitted

15. Concomitant active autoimmune disease

16. Prior experimental therapy/cancer vaccine treatment

17. Current immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 1 month of study entry

18. History of blood transfusion reactions

19. Known allergy to bovine products

20. Know allergy to murine products

21. Progressive viral/bacterial infection. All infections must be resolved and the patient must remain afebrile for 7days without antibiotics prior to enrollment

22. Cardiac disease of symptomatic nature or cardiac ejection fraction < 45%

23. History of HIV positivity or AIDS

24. Psychiatric/addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation

25. Concurrent medication known to interfere with platelet function or coagulation (e.g., aspirin, ibuprofen, clopidogrel, or warfarin) unless can be discontinued for an appropriate time period based on the drug half-life and known activity (e.g., aspirin for 7 days) prior to cryoablation procedure

26. Use of low molecular weight heparin preparations unless can be discontinued 8 hours prior to cryoablation

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
AlloStim
AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.
Procedure:
Cryoablation
Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.

Locations

Country Name City State
United States Medical Oncology Associates of San Diego San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Immunovative Therapies, Ltd.

Country where clinical trial is conducted

United States, 

References & Publications (5)

Har-Noy M, Slavin S. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Med Hypotheses. 2008;70(6):1186-92. Epub 2007 Dec 3. — View Citation

Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. — View Citation

Har-Noy M, Zeira M, Weiss L, Slavin S. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity. Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007 — View Citation

Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to — View Citation

LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M, Bonnotte B, Katsanis E, Larmonier N. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-?-dependent mechanism. J Immunol. 2011 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Immunological Response Blood samples will be evaluated for immunological response and a determination made as to whether immunological response correlates with RECIST and pathology. 90 days after last dose administration
Other Anti-Tumor Response The changes in tumor burden by RECIST and compare these changes with the pathological analysis of corresponding biopsies. 90 days after last dose administration
Primary To determine the safety of increased frequency of dosing Three patients are enrolled at each frequency schedule in the absence of dose limiting toxicity (DLT). A DLT is defined as any allergic or autoimmune toxicity or other study drug related toxicity Grade 3 or higher during the DLT assessment window. Window is defined as the time required receiving two doses of AlloStim IV push plus 28 days follow-up
Secondary Health-Related Quality of Life Health-Related Quality of life will be measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) and its supplementary breast cancer questionnaire (QLQ-BR23). From enrollment to 90 days after last dose administration.
Secondary Evaluate the anti-tumor effect of Allostim combined with cryoablation at the new proposed dose and frequency schedule. Each treatment schedule will be monitored for radiological, pathological, and immunological response. These assessments will be compared between three treatment schedules. 90 days after last dose administration
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2